Samsung Bioepis will take over the commercialization of BYOOVIZ® in Europe from January 2026 following a deal with Biogen, aiming to expand its presence in the growing biosimilars market.

Information on the Target

Samsung Bioepis is set to take full commercial control of BYOOVIZ® (ranibizumab) starting January 2026, following a complete transition of commercialization rights from Biogen. BYOOVIZ, which received approval from the European Commission (EC) in August 2021, is the first ophthalmology biosimilar launched in Europe and has been available in several countries since March 2023.

BYOOVIZ is designed to treat various conditions, including Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). The asset's commercial viability is significantly boosted by its established presence and marketing potential within the European market.

Industry Overview in Europe

The biosimilars industry in Europe has evolved rapidly, with a growing acceptance of biosimilar therapies in various therapeutic areas, including oncology, immunology, and ophthalmology. Regulatory